FDA Approves Bedford's Adriamycin

Adriamycin is a chemotherapy drug that is administered for the treatment of several types of cancer, including multiple myeloma, bladder cancer, breast cancer, leukemia, and lymphomas.

It functions as an antineoplastic, cytotoxic drug, meaning that it is toxic to rapidly growing cells, such as tumors.

Adriamycin is used for:
Treating various types of cancer.

Adriamycin is an antineoplastic antibiotic. It works by killing cancer cells.

Adriamycin, an active medicine against many cancers, is one of the older chemotherapy drugs, having been in use for decades. Adriamycin is a clear, orange-red colored powder or liquid, which is administered intravenously only. It is most commonly used in treatment of the following cancers:




Multiple Myeloma


Bone tumors

Use For Breast Cancer:
Adriamycin can be used to treat early-stage or node-postive breast cancer, HER2-positive breast cancer, and metastatic disease. Adriamycin is sometimes combined with cytoxan and/or 5-flouracil to make a cocktail of breast-cancer fighting chemotherapy drugs.

Other Uses for Adriamycin:
This drug is also used to treat other cancer, including ovarian, bladder, lung, thyroid and gastric cancers, as well as neuroblastoma, lymphoma, leukemia, and Kaposi's sarcoma.

How Adriamycin Works:
Adriamycin fights cancer by slowing or stopping the growth of cancer cells. This drug gets inside the DNA of cancer cells and prevents cell replication by inhibiting protein synthesis. Adriamycin also forms oxygen free radicals, which can result in heart and circulatory damage.